Skip to main content

Transforming lives with groundbreaking technologies that address irregular heart rhythms, heart failure and sudden cardiac arrest

Confidently moving forward

Confidently moving forward

Hear Mike’s story
   
We are collaborating with healthcare professionals to help reduce costs, improve outcomes and enhance patients' lives with the most advanced and least invasive rhythm management technologies available.

Delivering Meaningful Innovation

Redefining Heart Care. We’re dedicated to helping patients live longer, healthier lives with the RHYTHMIA HDx™ Mapping System which provides physicians with the ability to diagnose arrhythmias with greater efficiency, delivers targeted therapy and confidently achieves procedural endpoints in complex substrates.

Improving Patient Management Through Personalized Care. Our MR-conditional Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogic™ Heart Failure Diagnostic to help physicians improve heart failure (HF) management. These devices also combine SmartCRT™ Technology and industry leading EnduraLife™ Battery Technology to improve patient management.

Pioneering Progressive ICD Therapy. The EMBLEM™ MRI S-ICD System is the first and only MR-conditional subcutaneous implantable defibrillator (S-ICD) that provides protection for patients at risk for sudden cardiac death while avoiding risks and complications associated with transvenous leads.

1st and only subcutaneous implantable defibrillator

2x our ICDs and CRT-Ds

HeartLogicTM Heart Failure Diagnostic

Conditions We Treat

  • Cardiac Arrhythmias
  • Heart Rhythm Disorders
  • Sudden Cardiac Arrest
  • Heart Failure
  

ablation cases worldwide

33.5 million people globally have atrial fibrillation

Solutions We Offer

  • Pacemakers
  • Implantable cardioverter defibrillators (ICDs)
  • Subcutaneous implantable defibrillator (S-ICD)
  • Cardiac resynchronization therapy defibrillators (CRT-Ds)
  • Remote monitoring systems
  • Pacing and ICD leads
  • Mapping and navigation system
  • Insertable cardiac monitors (ICMs)
  • Diagnostic and therapeutic catheters
  • Electrophysiology recording system
  • Intracardiac access sheaths
  • Pericardiocentesis kits
Activation Map
The RHYTHMIA HDxTM Mapping System provides unprecedented clarity to diagnose with greater efficiency, deliver targeted therapy and confidently achieve procedural endpoints in complex substrates. RHYTHMIA HDx is now available with DIRECTSENSE™ Technology, which features a unique local impedance measure that reveals powerful insights into tissues resistivity and subsurface heating during radiofrequency ablation procedures.
Resonate X4
The ResonateTM family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogicTM Heart Failure Diagnostic. The Resonate devices, which are approved by the U.S. Food and Drug Administration for conditional use in a magnetic resonance imaging (MRI) environment, also combine the company's SmartCRTTM Technology with industry-leading EnduraLifeTM Battery Technology to improve patient management through personalized care.
Emblem MRI S-ICD System
The EMBLEMTM MRI S-ICD System is the first and only subcutaneous implantable defibrillator that provides protection for patients at risk for sudden cardiac death while avoiding risks and complications associated with transvenous leads.
LUX-Dx™ ICM System
The LUX-Dx™ ICM System is a long-term diagnostic device implanted in patients to detect arrhythmias associated with conditions such as atrial fibrillation, cryptogenic stroke and syncope. Designed with a dual-stage algorithm that detects and then verifies potential arrhythmias before an alert is sent to clinicians, it provides actionable data from clinical decision making.
  

Sources

1.  Ellis C, Markus T, Dickerman D, Orton J, Hassan S, Good E, Okabe T, Greenspon A. Ampere Hour as a Predictor of CRT ICD Pulse Generator Longevity: A Multi-Center Study. Presented at HFSA 2014. https://www.onlinejcf.com/article/S1071-9164(14)00337-6/fulltext. Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity Study. The five major institutions performing the study include, at Vanderbilt University, Eastside Cardiovascular Medicine, University of Michigan, Thomas Jefferson University, Robert Wood Johnson University Hospital, Cooper Health System and North Ohio Research. Boston Scientific = 266 patients, Medtronic = 542 patients, St. Jude Medical = 149 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

2.  Boehmer, JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices; Results from the MultiSENSE study. JACC Heart Fail. 2017 Mar:5(3)216-25.

3.  NHANES data. Source: Heart Disease and Stroke Statistics – 2019 Update.
https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000659

4.  The ratio is calculated from Decision Resources Group. Source: DRG’s Medtech 360 Reports on Electrophysiology Mapping and Ablation Devices in Europe, LATAM, APAC and US (https://decisionresourcesgroup.com/report/548221-medtech-electrophysiology-mapping-and-ablation-devices/)

5.  Worldwide Epidemiology of Atrial Fibrillation, A Global Burden of Disease 2010 Study, Citation, 2013. (https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.113.005119)

Top